Abstract
Background: Corneal allogenic intrastromal ring segments (CAIRSs) offer a novel, biocompatible alternative to synthetic intracorneal ring segments (ICRSs). This review aims to evaluate the clinical outcomes of CAIRS. Methods: Inclusion criteria were studies with a minimum of 20 eyes and six months of follow up. The primary outcome measure was uncorrected distance visual acuity (UDVA). The secondary outcomes were a change in corrected distance visual acuity (CDVA), spherical equivalent (SE), mean keratometry (K-mean), maximum keratometry (K-max), K1, K2, and pachymetry. Results: The primary outcome UDVA improved from 0.83 ± 0.15 to 0.40 ± 0.08 logMAR (p = 0.01), while CDVA improved from 0.52 ± 0.22 to 0.19 ± 0.09 logMAR (p = 0.01). K-max decreased from 57.8 ± 1.09 D to 53.57 ± 2.66 D (p < 0.01), and K-mean reduced from 49.27 ± 0.28 D to 45.30 ± 1.46 D (p < 0.01). An average of 84.92% ± 11.4% of eyes had an improvement in UDVA. No major complications or significant visual acuity deterioration were reported. Conclusions: CAIRSs serve as an alternative to synthetic ICRSs and even corneal transplantation in some cases. They represent a safe, effective, and biocompatible promising advancement in corneal ectasia management to improve visual acuity and corneal topography with minimal complications.